Advances in the understanding and treatment of Cutaneous T-cell Lymphoma

Farrah S. Bakr and Sean J. Whittaker*

St. John’s Institute of Dermatology, School of Basic and Biomedical Sciences, Kings College London, London, United Kingdom

Cutaneous T-cell lymphomas (CTCL) are a heterogeneous group of non-Hodgkin’s lymphomas (NHL) characterised by the clonal proliferation of malignant, skin homing T-cells. Recent advances have been made in understanding the molecular pathogenesis of CTCL. Multiple deep sequencing studies have revealed a complex genomic landscape with large numbers of novel single nucleotide variants (SNVs) and copy number variations (CNVs). Commonly perturbed genes include those involved in T-cell receptor signalling, T-cell proliferation, differentiation and survival, epigenetic regulators as well as genes involved in genome maintenance and DNA repair. In addition, studies in CTCL have identified a dominant UV mutational signature in contrast to systemic T-cell lymphomas and this likely contributes to the high tumour mutational burden. As current treatment options for advanced stages of CTCL are associated with short-lived responses, targeting these deregulated pathways could provide novel therapeutic approaches for patients. In this review article we summarise the key pathways disrupted in CTCL and discuss the potential therapeutic implications of these findings.

KEYWORDS
cutaneous T cell lymphoma (CTCL), dermatology, pathway targeted interventions, genomics, cutaneous lymphoma

Introduction

Cutaneous T-cell lymphomas are a heterogeneous group of Non-Hodgkin’s lymphomas of which Mycosis Fungoides (MF) is responsible for almost 50% of all primary cutaneous lymphomas (1). They display wide variation in relation to their clinical, histopathological, immunophenotypic and underlying biologic features (1, 2). CTCLs are amongst a wider group of mature T-cell malignancies of which the more common subtypes are Peripheral T-cell lymphoma, Not Otherwise Specified (PTCL nos) and systemic anaplastic large cell lymphoma (ALCL). A rare HTLV-1 driven subtype of T-cell lymphoma known as Adult T-Cell Leukaemia/Lymphoma (ATLL) shares several phenotypic and genetic features with Sézary syndrome (SS) (3). Though MF/SS are the
focus of this review, we will compare and contrast genomic abnormalities of MF/SS with other CTCL variants and systemic T-cell lymphomas and highlight potential novel therapeutic strategies.

Genomic landscape of Mycosis fungoides and Sézary syndrome

In recent years, multiple high-throughput next-generation sequencing (NGS) studies have identified a complex genomic landscape in MF/SS, including high rates of somatic non-synonymous variants (SNVs) and copy number variants (CNVs) (4–13). The majority of studies have utilised whole exome sequencing (WES) of peripheral blood samples enriched for CD4+ leukemic T-cells from SS patients (4–9, 12, 13). Fewer samples from advanced stage MF have been analysed (n=56) by WES or whole genome sequencing (WGS) platforms (4, 5, 7, 10–12). An independent analysis of genomic data published prior to 2017 encompassing 220 CTCL cases (186 SS, 25 MF; 9 CTCL NOS) has highlighted at least 55 putative driver genes affecting multiple signalling pathways (13). Interestingly, there is significant overlap between MF and SS in the pathways affected. Commonly perturbed genes include those involved in TCR signalling pathways (PLCG1; CARD11; CD28; RLTPR) and those that selectively up-regulate the NFκB pathway (13). Other disrupted pathways include the DNA damage response (TP53; POT1; ATM; BRCA1-2), chromatin modification (ARID1A; TRRAP; DNMT3A; TET2) and JAK STAT signalling (STAT3; JAK3). Critically the aforementioned gene variants have been functionally validated confirming their driver gene status (4–8, 12–14). A summary of the pathways and their associated gene mutations is provided in Table 1.

There is limited data available on chromosomal rearrangements in view of the small WGS datasets from advanced MF samples. However, complex patterns of chromosomal rearrangements and translocations with no recurrent balanced translocations have been frequently identified with specific gains (17q, 8q) and losses (10q, 17p) (24).

T-cell signalling and differentiation

Mutations in PLCG1 and CARD11 are two of the most frequently observed in MF/SS. They appear to be mutually exclusive and occur in almost 30% of SS cases (13). These gain of function mutations increase downstream T-cell signalling specifically through enhanced NFκB, NFAT and API transcriptional activity (12, 14). These transcription factors regulate the expression of genes involved in cell proliferation, survival and differentiation. Crucially, there is evidence that many of these variants induce constitutive activation of downstream T-cell signalling without T-cell stimulation (12, 14). Furthermore, CTLA4-CD28 and ICOS-CD28 gene fusions enhance CD28 dependent T-cell signalling, and RLTPR variants activate the NFκB pathway thereby increasing downstream TCR signalling (7, 13). The high prevalence of these of NFκB pathway gene variants in CTCL supported by functional data indicates that there is a critical selection pressure for activation of the NFκB pathway in the transformation of mature T-cells.

PLCG1 mutations have also been detected in other mature T-cell malignancies, notably HTLV-1 associated ATLL (25), PTCL(NOS) (26), hepato-splenic T-cell lymphomas (27) andAITL (28) with the PLCG1 p.S345F and R48W variants being two of the most frequently reported. In addition, mutations of the JAK-STAT, CD28, VAV1, DNMT3A and TET2 genes are also reported in other mature T-cell malignancies (4–9, 25–28).

Enhanced T-cell activation via the T-cell receptor and NFκB pathway, leads to downstream activation of multiple pathways including the Janus tyrosine kinase (JAK) Signal transducers and activators of transcription (STAT) pathway. These proteins have a multitude of functions including TH cell proliferation and differentiation, as well as gene regulation and epigenetic modification. Unlike the STAT proteins, gain of function mutations in the JAK proteins are infrequently observed. However, copy number gains of both STAT3 and STAT5B are common and associated with constitutive expression of these key transcription factors (29, 30).

Epigenetic modification

Epigenetic changes include DNA and histone modifications which affect gene transcription and regulate cell differentiation. Furthermore, epigenetic modification is critical for sustaining the transcriptional memory for T-cells allowing rapid transcription of inducible genes upon activation (31, 32). Global hypomethylation is a consistent feature of malignancy and contributes to genomic instability but DNA methylation of gene promoters can lead to gene silencing. Crucially these changes are observed in MF/SS with evidence for hypomethylation of 7.8% of CpG sites in SS, and hypermethylation of 3.2% of CpG sites, specifically in the proximal region of promoters (33). There is extensive evidence that promoter hypermethylation leads to the silencing of specific tumour suppressor genes in MF/SS including those involved in cell cycle regulation (CDKN2A/2B) (34), DNA repair (MLH1 and MGMT) (35), apoptosis (FAS) (36) and JAK-STAT signalling (SHP-1) (37). Methylation of cytosine residues to 5-methylcytosine is mediated by DNA methyltransferases (DNMTs) and gain of function mutations of DNMT3A have been frequently identified in haematologic malignancies including MF/SS (4, 5, 8, 9). A second type of DNA methylation involves 5-hydroxymethylation of cytosine which is mediated by ten-eleven translocation 1-3 enzymes (TET1-3) but, in contrast to 5-methylcytosine, this is associated with enhanced gene expression (38). Loss of function TET2
### TABLE 1  
Major aberrant pathways and associated emerging systemic therapies for advanced MF/SS.

| Pathway                          | Gene                        | Systemic agent class | Agent name | Mechanism of action                                                                 | References |
|----------------------------------|-----------------------------|----------------------|------------|-------------------------------------------------------------------------------------|------------|
| TCR Signalling                   | PLCG1                        | In development       | PLCG1 inhibitor | Inhibition of PLCG1 leading to decreased TCR signalling                              | –          |
|                                  | CD28                         |                      | PRKCB/Q inhibitor | Inhibition of STAT3, leading to decreased cell proliferation and apoptosis in pre-clinical studies. | Garcia-Diaz (15) |
|                                  | CARD11                       |                      | PTPR2       |                                                     | –          |
|                                  | PRKCB/Q                      |                      | JAK1-3       |                                                     | –          |
|                                  | STAT3-5                      |                      | JAK inhibitor | JAK1/2 inhibitor. Dysregulated JAK-STAT pathway in CTCL leads to T-cell activation. Phase II trial showed 23% ORR. | Moskowitz (16) |
| DNA Damage Repair                | ATM                          |                      | ATR inhibitor | Synthetic lethality in view of HR defects. Decreased cell viability in SS cells and increased sensitivity to phototherapy in CTCL cell lines in pre-clinical studies. | Biskup (17), Pinzaru (3) |
| Chromatin Modification           | TET2                         | HDAC inhibitor       | Resminostat  | HDACi modify acetylation sites in proteins leading to dysregulated gene transcription, cell cycle arrest and apoptosis. Resminostat phase II trial ongoing (RESMAIN NCT02953301). Vorinostat and Romidepsin are FDA and EMA approved. | Olsen (18), Whittaker (19) |
| Cell cycle                       | CDKN2A                       | –                   | –           |                                                     | –          |
| NF-kB pathway                    | TNF-α                        | Proteasome inhibitor | Bortezomib   | Inhibits the degradation of the nuclear factor kappa B (NFκB) inhibitor luxBt. Phase II trial showed 67% ORR. | Zinzani (20) |
| T-cell migration                 | CCR4                         | CCR4 antibody       | Mogalizumab  | Increased CCR4 expression seen in CTCL. Phase III trial (MAVORIC) of CCR4 inhibitor leads to increased DFS and OR vs. Vorinostat in SS. | Kim (21) |
| MAPK pathway                     | NF1                          | –                   | –           |                                                     | –          |
| P13K pathway                     | VAV1                         | Phosphatidylinositol 3-kinase (P13K) inhibitor | Duvelisib | PI3K-δ and PI3K-γ active in leucocytes and important for modulating immune response and tumour microenvironment. Phase I trial showed 32% ORR. | Horwitz (22) |
| PD-1 pathway                     | PRKCB                        | Anti-PD1/PD-L1 inhibitors | Pembrolizumab | Increased PD-1 expression in CTCL. Inhibition enhances cytotoxic T-cell killing. Phase II trial showed 38% ORR. | Khodadoust (23) |

A summary of the main pathways harbouring putative driver gene mutations or copy number changes in MF/SS. Novel systemic therapies targeting these pathways currently under investigation are also highlighted. FDA, US Food and Drug Administration; EMA, European Medicines Agency.
mutations are well documented in SS (5, 7–9, 30). In SS, there is also mutational selection pressure for genes involved in other epigenetic modifications including IDH encoding isocitrate dehydrogenases which inhibit TET proteins, ARID1A/1B which affect chromatin modelling and MLL genes which mediate histone methyltransferases (4, 8, 9, 30). Large epigenomic studies in MF/SS have shown that the methylation pattern of leukemic T-cells in SS can be similar to that of regulatory T-cells and that there is almost universal activation of NFκB (39). Recent data suggest that hypermethylation of the hTERT promoter in MF/SS may be associated with telomerase activation (40).

MicroRNA (miRs), one of a group of non-coding RNA transcripts, are key post-transcriptional regulators of mRNA and are known to affect both the stability and translation of mRNA. In MF/SS, miR dysregulation has been observed with aberrant expression linked to abnormal DNA methylation of miR promoters as well as copy number changes (41). In addition, constitutive activation of STAT3/5 has been shown to enhance miR-155 and miR-21 expression leading to increased apoptosis resistance and Th2 proliferation (41).

DNA damage response pathways and telomere instability

The DNA damage response (DDR) consists of numerous complex and inter-dependent signalling pathways which either maintain cell viability by repair of DNA or direct the damaged cell to undergo senescence or programmed cell death. Inevitably this complex process is closely linked with pathways regulating the cell cycle, chromatin remodelling and apoptosis (42). Previous cytogenetic and array CGH studies in MF/SS identified complex structural and numerical chromosomal abnormalities (24). More recent WGS and WES studies have confirmed a high degree of genomic instability with over 60 gene aberrations reported across all 5 DDR pathways (5, 8–10). One study of 101 SS samples identified SNVs and/or CNVs affecting genes involved in DNA repair and telomere maintenance in over 50% of cases. Notably, SNVs and CNVs affecting genes involved in homologous recombination such as RAD51C, BRAC2 and POLD1, are also detected in MF/SS (9). TP53 is the most commonly mutated gene in CTCL with loss of function SNVs and deletions which lead to a significant detrimental effect on the DNA damage response and telomere stability.

Telomere dysregulation is a recognised feature of MF/SS where shortened telomeres have been observed (43, 44). Furthermore, mutations in POT1, encoding a telomere binding protein are also frequently detected in MF/SS and ATLL (4, 5, 8–11, 25, 30, 45) and studies suggest that these loss of function variants likely contribute to telomere dysfunction by abolishing telomere binding and inducing DNA damage at telomeres in the form of telomere induced foci (TIFs) (3, 46–51). Cell cycle dysregulation is a major contributor to tumorigenesis in MF/SS. Mutation or deletions have been reported in several cell cycle checkpoint and tumour suppressor genes including CDKN1, CDKN2A, CDKN2B, ATM, ATR, TP53, RB1 and PTEN (4, 5, 8–10). Loss of function ATM mutations have been reported in several T-cell lymphomas (25, 26, 52–60) including MF/SS (9–11) and ATR mutations are also observed in MF/SS and NK T-cell lymphoma (5, 6, 10, 11, 61). In view of the key role of these kinases in the DDR and in cell cycle regulation, pathway disruption either by gene mutation or as a result of telomere dysfunction is likely to contribute to the genomic instability seen in MF/SS.

CTCL evolution

As the vast majority of studies have been conducted in samples from advanced stages of MF or leukaemic SS samples, until recently there has been little insight into the driver events in early-stage disease. In solid malignancies, the use of mathematical modelling of WGS/WES data has deepened understanding of the evolution of genomic events and the impact of intra-tumour heterogeneity on therapeutic response (62). The use of paired plaques and tumours from MF patients has demonstrated that sub-clonal evolution is a feature of MF and is linked to disease progression, however, as yet these preliminary studies have failed to identify a common series of genomic events in early stages of disease (11).

CTCL causation

A series of mutational signatures have been identified which are linked to a combination of intrinsic and extrinsic mutagens, and have been associated with specific malignancies (63, 64). The presence of these mutational signatures in clonally expanded cell populations is determined by assessing the six substitution types and their 5’ and 3’ nucleotide context giving 96 different trinucleotide mutation types. A recent meta-analysis of whole exome sequencing (WES) data from 403 patients across several T-cell NHL subtypes, including 6 MF/SS studies has revealed that the UV signature (signature 7) was exclusively present in MF/SS. It accounted for the mutational burden in 52% of MF and 23% of SS cases (65). In addition, these C>T/CC>TT mutations at dipyrimidine sites had a significant bias towards the untranscribed strand which is a feature of transcription-coupled nucleotide excision repair associated with UV-induced mutations (66). Crucially, the presence of this signature (7.5–88% of the overall SNVs) in CD4+ cells isolated from the blood of SS patients suggests that these malignant T-cells either circulate freely from the skin to the blood compartment or develop from skin resident memory T-cells. A significant proportion of patients analysed (41%) were treatment naive
and the detection of a mutational signature is dependent on the presence of a clonal population suggesting that the malignant T-cell in MF/SS accumulates UV associated mutations before transformation and clonal expansion.

Similar to other malignancies linked to exogenous mutagens (e.g. non-melanoma and melanoma skin cancers and smoking-associated lung cancers), MF/SS exhibit a very high mutational load, and are unique amongst other types of T-cell lymphoma which carry a much lower mutational burden. These data confirm the significant contribution of environmental UV exposure to the mutational burden in MF and SS and UV is a likely causal factor in the transformation of T-cells that are either circulating through or resident in skin.

Other CTCL variants

Primary cutaneous CD30+ lymphoproliferative disorders (pcALCL/LYP)

Primary cutaneous CD30+ anaplastic large cell lymphoma (pcALCL) has similar genomic alterations to its systemic counterpart albeit at much lower frequency. Most fail to express anaplastic lymphoma kinase (ALK), but have an excellent prognosis (67). In a small proportion of patients mutations of JAK1 and/or STAT3 and NPM1-TYK2 gene fusions have been reported in pcCD30+ALCL (68).

Chromosomal rearrangements involving the DUSP22-IRF4 (MUM1) locus on 6p25.3 have also been identified in both pcCD30+ ALCL (25%) and less commonly (5%) in lymphomatoid papulosis (LYP) (69), but MUM1 expression is not specific for this rearrangement.

Subcutaneous panniculitis-like T-cell lymphoma (SPTCL)

The majority of cases harbour one of two homozygous loss of function germline HAVCR2 variants (pTyr82Cys and p.Ile97Met) observed in Polynesian/East Asian and European origin respectively (70). HAVCR2 encodes T-cell immunoglobulin mucin 3 (TIM-3) is expressed by CD8+ T-cells and NK cells and regulates peripheral tolerance, innate immunity and inflammatory responses. Somatic variants have also been detected in genes involved in epigenetic modification (TET2, ARID1B), the PI3K/akt/mTOR and JAK-STAT pathways (71).

Primary cutaneous γδ T-cell lymphomas

Similar to MF/SS, mutations in the JAK/STAT, MAPK, MYC and chromatin modification pathways have been detected, but interestingly, TCR-CD28 signalling pathway mutations have also been reported (72). In addition, panniculitic Vδ2 T-cell lymphomas do not show germline mutations of HAVCR2 as seen in a majority of γδ SPTCL patients (72).

Prognostic biomarkers

The prognosis for patients with MF/SS is variable even amongst patients with the same stage of disease. This has been partly addressed by the proposal of clinical prognostic models such as the CLIPi (73, 74) which is currently the subject of a multi-centre prospective study. In view of the genomic heterogeneity observed in MF/SS, it is likely that a more accurate prognostic model will require analysis of genetic clusters which may include a combination of gene mutations including SNVs and CNVs. There is some evidence that specific genomic clusters can be defined in SS (75), however, there has been no clinical correlation with patient outcomes to date. Furthermore, the paucity of genomic data in MF highlights the need for further NGS studies, particularly in early stage disease.

Therapeutic implications

In view of the genomic heterogeneity in MF/SS reflecting the underlying high rate of UV signature mutations, a single targeted treatment option is unlikely to be effective. However, a deeper understanding of the genomic landscape could provide insight into potential therapeutic approaches especially in early stage disease (76). Stratification of individual patients according to mutational profile/deregulated pathway could allow the use of existing treatments such as 1pilimumab (CD28-CTLA4 fusion), Ruxolitinib and Tofacitinib (JAK mutations or JAK2 fusions as detected in rare aggressive cytotoxic CTCL variants) (77, 78) and Bortezomib (NFkB pathway) (79). Patients with abnormalities of epigenetic regulation such as DNMT3A and TET2 could be selected for treatment with demethylating agents such as 5-Azadecitidine and/or HDACi, whilst those with RHOA mutations could be eligible for PI3K inhibitors (Duvelisib). However, an alternative is to consider a tumour agnostic approach and the genomic landscape of MF/SS including marked genomic instability suggest that targeting the DDR pathway might be a productive strategy. A summary of emerging treatments targeting the various dysregulated pathways in MF/SS is provided in Table 1.

Restoration of Th1/Th2 immune profile

In view of the immune dysregulation profile seen in advanced MF/SS with a diminished Th1 immune response (IFN-gamma, IL-12) and skewing towards a Th2 immune profile (increased IL-4, IL-5 and/or IL-13) (80), interferons (IFN-alpha and IFN-gamma) were amongst the first immunotherapies to be used. IFN-alpha has been shown to stimulate antitumour cytotoxicity by activating CD8+ T-cells and NK cells and restores the Th1/Th2 balance by reducing IL-4 and IL-5 production by malignant T-cells (81, 82). IFN-gamma acts similarly to IFN-alpha by activating CD8+ and NK cells and...
increasing Th1 cytokine profile (80). IFN-alpha is EMA approved and effective in early stage patients who are refractory to skin-directed therapies (83), in which case it can be combined with phototherapy (84). Several clinical trials have highlighted the potential use of recombinant IL-12 as a novel immunotherapy with encouraging results (85–87).

**Targeted therapies**

There are currently several trials underway targeting checkpoint molecules (88, 89). Mogamulizumab, an anti-CCR4 monoclonal antibody has recently been approved by FDA and EMA following a phase III clinical trial which showed increased progression free survival (PFS) compared with the HDAC inhibitor, Vorinostat (21). Recently, it has emerged that Mogamulizumab also contributes to efficient immune restoration involving CD8+ as well as stem and memory CD4+ cells (90).

Pembrolizumab and Nivolumab inhibit the PD-1 receptor which enhances cytotoxic T-cell killing and have shown clinical responses in phase I and II trials (23, 91, 92). Whilst the high mutational burden of MF/SS would suggest that immunotherapies should be successful, the modest responses from these phase II trials (93) highlight the challenges of using a PD-1 inhibitor on a T-cell lymphoma which can express PD-1. Specifically there are two scenarios: PD-1 expression might reflect underlying gain of function mutations which would benefit from inhibition and there is emerging data suggesting that PD-1 mutations can be detected in some MF/SS patients (94), or PD-1 inhibition might reverse the tumour cell exhaustion leading to activation and proliferation of malignant T-cells. Whilst this second scenario has not yet been seen in MF/SS patients receiving PD-1 inhibitors, a phase II trial of Nivolumab in ATLL was discontinued because of rapid disease progression (95).

Targeting of CD47 with intralesional or intravenous TTI-621 has been used in patients with relapsed or refractory MF/SS in recent phase I trials with encouraging results (96, 97). Recent reports have shown that the CD39-CD73-adenosine pathway generates an immunosuppressive tumour microenvironment in SS and this provides a potential option to use emerging novel therapeutic approaches to target this pathway possibly in combination with checkpoint inhibitors or Mogamulizumab (98, 99).

**DNA damage repair pathway**

Perhaps the most interesting option would be tumour agnostic therapies targeting the DNA damage response (DDR) pathways which show considerable promise in various solid malignancies often as maintenance therapies after platinum-based chemo regimens (42). The DDR pathways are a vast network of over 450 proteins. These therapeutic approaches build on the success of PARP inhibitors inducing synthetic lethality in homologous recombination (HR) deficient malignancies (due to BRCA1 or BRCA2 loss). In view of the somatic mutations or deletions of HR genes (including ATM, BRCA1, BRCA2, Chk2, RAD50, RAD51C), these could be repositioned for use in MF/SS patients (Figure 1). Several ATR inhibitors are in early clinical development for use in both solid and haematological malignancies (100, 101). There is increasing evidence that ATR inhibition may be a potential therapeutic target in MF/SS. Small molecule inhibitors of ATR and Chk1 (VE-821/2 and Chir-124) have been shown to sensitize MF/SS cell lines to phototherapy by inducing apoptosis (17). In addition, cells overexpressing POT1 mutants (p.F62V and

---

**FIGURE 1**

ATM and ATR DDR pathways. The ATM and ATR pathways respond to different types of DNA damage with separate sensors (purple), mediators (blue) and transducers (red). Synthetic lethality can be exploited for cells with aberrant DDR pathways. Cells harbouring LOF mutations in one pathway have increased reliance on the other pathway for DNA damage repair. Inhibition of the intact pathway prevents p53-mediated DNA repair, cell cycle arrest and apoptosis. This results in accumulation of unrepaired DNA damage, mitotic catastrophe triggering p53-independent cell death. Pharmacological agents targeting components of the ATM/ATR pathways currently in clinical development are highlighted.
p.K90E) treated with an ATR inhibitor (ETP-46464) resulted in significant abrogation of TIFs (3). ATM inhibition has also been shown to overcome HDAC inhibitor resistance in both B and T-cell derived lymphomas including MF/SS, providing a rationale for combination therapy (102). Acting immediately downstream of ATR, targeting of Chk1 is effective in MYC-driven tumours including B-cell lymphomas owing to MYC-induced replication stress (103). Amplification of the MYC oncogene is one of the most commonly observed aberrations in MF/SS (4) which could increase replication stress in these cells and hence increase their sensitivity to ATR and/or Chk1 inhibitors. Furthermore, Chk1 inhibitors synergise with a number of therapeutic agents to induce cell death in MF/SS including the proteasome inhibitor, Ixazomib (104) and phototherapy (17).

Conclusions

Despite the wide range of treatment options currently available for MF/SS, therapeutic responses are invariably in the region of 30% and usually short lived (105), highlighting the need for a better understanding of the pathogenic mechanisms which would enable the development of more targeted therapies. A deeper understanding of dysregulated pathways and immunology in recent years has facilitated the development of several novel drugs currently in clinical trials. In addition to modulating pathways such as the JAK-STAT and NFκB pathways and immune check-points, targeting genomic instability and the DDR present an exciting novel treatment approach for T-cell malignancies such as MF/SS.

Author contributions

FB and SW planned and wrote the manuscript. Figure and table was generated by FB. All authors contributed to the article and approved the submitted version.

Funding

Open access fees are provided by King’s College London via the grant code: ST461.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The reviewer VG declared a past collaboration with the author SW to the handling editor.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Bradford PT, Devesa SS, Anderson WF and Toro JR. Cutaneous lymphoma incidence patterns in the united states: A population-based study of 3884 cases. Blood (2009) 113:5064–73. doi: 10.1182/blood-2008-10-184168
2. Kim EI, Hess S, Richardson SK, Newton S, Showe LC, Benoit BM, et al. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest (2005) 115(4):798–812. doi: 10.1172/JCI200524826
3. Pinaza AM, Hom RA, Beal A, Phillips AF, Ni E, Cardozo T, et al. Telomere replication stress induced by POT1 inactivation accelerates tumorigenesis. Cell Rep (2016) 15:2170–84. doi: 10.1016/j.celrep.2016.05.008
4. Choi J, Goh G, Walradt T, Hong BS, Bunick CG, Chen K, et al. Genomic landscape of cutaneous T cell lymphoma. Nat Genet (2015) 47:1011–9. doi: 10.1038/ng.3356
5. Da Silva Almeida AC, Abate F, Khiabanian H, Martinez-Escala E, Gutierrez T, Tensen CP, et al. The mutational landscape of cutaneous T cell lymphoma and sezary syndrome. Nat Genet (2015) 47:1465–70. doi: 10.1038/ng.3442
6. Prasad A, Rabionet R, Espinet B, Zapata L, Dzuynski R, Dahlman KB, Zic JA, et al. Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides. Blood (2015) 126:508–19. doi: 10.1182/blood-2014-11-611194
7. Yierr A, Hennessey D, O’Keefe S, Patterson J, Wang W, Wong GKS, et al. Branched evolution and genomic intratumor heterogeneity in the pathogenesis of cutaneous T-cell lymphoma. Blood Adv (2020) 4(11):2489–500. doi: 10.1182/bloodadvances.202000441
8. Vaqué JP, Gómez-López G, Monsálvez V, Varela J, Martínez N, Pérez C, et al. PLCG1 mutations in cutaneous T-cell lymphomas. Blood (2014) 123:2034–43. doi: 10.1182/blood-2013-05-504308
9. Woolard WJ, Pullabhada V, Leonc A, Patel VM, Butler RM, Bayega A, et al. Candidate driver genes involved in genome maintenance and DNA repair in sezary syndrome. Blood (2016) 127:3387–97. doi: 10.1182/blood-2016-02-699843
10. McGirt LV, Jia P, Barrenwald DA, Dzuynski RJ, Dahlman KB, Zic JA, et al. Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides. Blood (2015) 126:508–19. doi: 10.1182/blood-2014-11-611194
11. Park J, Yang J, Wenzel AT, Ramachandran A, Lee WJ, Daniels JC, et al. Genomic analysis of 220 CTCLs identifies a novel recurrent gain-of-function alteration in RLTPR (p.Q575E). Blood (2017) 130(12):1430–40. doi: 10.1182/blood-2017-02-768234
12. Patel VM, Flanagan CE, Martins M, Jones CL, Butler RM, Woolard WJ, et al. Frequent and persistent PLCG1 mutations in cutaneous T-cell lymphomas. Blood (2014) 123:2034–43. doi: 10.1182/blood-2013-05-504308
13. Park J, Yang J, Wenzel AT, Ramachandran A, Lee WJ, Daniels JC, et al. Genomic analysis of 220 CTCLs identifies a novel recurrent gain-of-function alteration in RLTPR (p.Q575E). Blood (2017) 130(12):1430–40. doi: 10.1182/blood-2017-02-768234
14. Patel VM, Flanagan CE, Martins M, Jones CL, Butler RM, Woolard WJ, et al. Frequent and persistent PLCG1 mutations in cutaneous T-cell lymphomas. Blood (2014) 123:2034–43. doi: 10.1182/blood-2013-05-504308
15. García-Diaz N., Casar B., Alonso-Alonso R., Quevedo L., Rodriguez M., Russo-Julve F., et al. (2022) PLCG1/PKCB downstream signaling controls cutaneous T-cell lymphoma development and progression. J. Invest. Dermatol. 142 (5), 1391–1400.e15. doi: 10.1016/j.jid.2021.09.024
16. Moskovitz AJ, Ghone P, Jacobsen E, Ruan J, Schatz JH, Noor S, et al. (2021). A biomarker-driven study of ruxolitinib demonstrates effectiveness of Jak/STAT targeting in T-cell lymphomas. Blood 138(6):2828–37. doi: 10.1182/blood.2020121337.

17. Biskup E, Naym DG and Gnadideki R. Small molecule inhibitors of ataxia telangectasia and Rad3 related kinase (ATR) sensitize lymphoma cells to UVA radiation. J Dermatol Sci 2016;84(3):239–47. doi: 10.1016/j.jdermsci.2016.09.010.

18. Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, et al. Phase II/III multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol (2007) 25(21): 3109–15. doi: 10.1200/JCO.2006.10.2434.

19. Whittaker SJ, Demierre MF, Kim EJ, Roop AH, Lerner A, Duvcic M, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol (2010) 28(29):4845–91. doi: 10.1200/JCO.2010.28.9066.

20. Zinzani PL, Musuraca G, Tani M, Stefoni V, Marchi E, Fina M, et al. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol (2007) 25(27):4283–97. doi: 10.1200/JCO.2007.11.4207.

21. Kim YH, Bagot M, Pinter-Brown L, Roop AK, Porcu P, Horwitz SM, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAYORIC). An international, open-label, randomised, controlled, phase III trial. Lancet Oncol 2019; 19(9):1192–204. doi: 10.1016/S1470-2045(18)30379-6.

22. Horwitz SM, Koch R, Porcu P, Oki Y, Moskovitz AJ, Perez M, et al. Activity of the FPRK-Lyn inhibitor duvelisib in a phase I trial and preclinical models of T-cell lymphoma. Blood. (2018) 131(8): 888–98. doi: 10.1182/blood.2017-082070.

23. Khodadoust MS, Roop AK, Porcu P, Foss FM, Moskovitz AJ, Shustov A, et al. Pembrolizumab in relapsed and refractory cutaneous T-cell lymphoma: A multicenter phase II study. J Clin Oncol (2020) 38(1):10–8. doi: 10.1200/JCO.2019.19.0106.

24. Mao X, Lillingston DM, Czelupkowskii B, Russell-Jones R, Young BD and Whittaker S. Molecular cytogenetic characterization of sezary syndrome: A multicenter phase II study. J Clin Oncol (2015) 47:1304. doi: 10.1200/JCO.19.01056.

25. Kataoka K, Nagata Y, Kitanaka A, Shiraishi Y, Shimamura T, Yasunaga J, et al. Integrated molecular analysis of adult T cell leukemia/lymphoma. FYN kinase in peripheral T cell lymphomas. Perez-Garcia A, et al. Recurrent mutations in epigenetic regulators, RHOA and PTEN in cutaneous T-cell lymphoma. Pembrolizumab in relapsed and refractory mycosis fungoides and sezary syndrome de

26. Pembrolizumab in relapsed and refractory mycosis fungoides and sezary syndrome. J Invest Dermatol (2020) 134(4):1116–25. doi: 10.1097/doi.2020.09.301.

27. Van Doorn R, Zoutman WH, Dijkman R, De Menezes RX, Commandeur S, Mulder AA, et al. Epigenetic profiling of cutaneous T-cell lymphoma. Promoter hypermethylation of multiple tumor suppressor genes including BCL6a, PTPRG, and p73. J Clin Oncol (2005) 23(17):3886–96. doi: 10.1200/JCO.2005.11.353.

28. Rasmussen KD and Helin K. Role of TET enzymes in DNA methylation, development, and cancer. Genes Dev (2016) 30(7):733–50. doi: 10.1101/ gad.276868.115.

29. Ou K, Zaba LC, Sapathy AT, Giresi PG, Li R, Jin Y, et al. Chromatin accessibility landscape of cutaneous T cell lymphoma and dynamic response to HDAC inhibitors. Cancer Cell (2017) 32(1):27–41.e4. doi: 10.1016/j.ccell.2017.05.008.

30. Chubb A, Roojo J, Pajapone J, Poglo S, Prochazkova-Carlotti M, Cherrier E, et al. Exploring hTERT promoter methylation in cutaneous T-cell lymphomas. Mol Oncol (2021) 16(9):1931–46. doi: 10.1016/j.molonc.2021.06.1294.

31. Glaud M, Willerslev-Olsen A, Gjerdrum LMR, Lindahl MB, Tuus BT, Andersen MH, et al. MicroRNAs in the pathogenesis, diagnosis, prognosis and targeted treatment of cutaneous T-cell lymphomas. Cancers (Basel) (2020) 12(5):1229. doi: 10.3390/cancers12051229.

32. Chevet E, Andrique L, Prochazkova-Carlotti M, Ferrer J, Cappellen D, Laharie R, et al. Telomerase functions beyond telomere maintenance in primary cutaneous T-cell lymphoma. Blood (2014) 123:1850–9. doi: 10.1182/blood-2013-05-500866.

33. Nagata Y, Kontani K, Enami T, Kataoka K, Iishi R, Totoki Y, et al. Variegated RHOA mutations in adult T-cell leukemia/lymphoma. Blood. (2012) 119:594–606. doi: 10.1182/blood-2011-06-44948.

34. Ramakrishna A, Quesada V, Foronda M, Conde L, Martinez-Trillos A, Villamor N, et al. POT1 mutations cause telomere dysfunction in chronic lymphocytic leukemia. Nat Genet (2013) 45:526–30. doi: 10.1038/ng.2584.

35. Shi J, Yang XR, Ballev B, Rotunno M, Calista D, Fargnoli MC, et al. Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma. Nat Genet (2014) 46:478–81. doi: 10.1038/ng.3047.

36. Robles-Exposito CD, Harland M, Ramsay AJ, Asude LG, Quesada V, Ding Z, et al. POT1 loss-of-function variants predispose to familial melanoma. Nat Genet (2015) 48:115–20. doi: 10.1038/ng.3184.

37. Van Doorn R, Zoutman WH, Slieker RC, Dijkman R, Commandeur S, Zoutman WH, De Menezes RX, Commandeur S, Mulder AA, et al. Epigenetic profiling of cutaneous T-cell lymphoma. Promoter hypermethylation of multiple tumor suppressor genes including BCL6a, PTPRG, and p73. J Clin Oncol (2005) 23(17):3886–96. doi: 10.1200/JCO.2005.11.353.

38. Rasmussen KD and Helin K. Role of TET enzymes in DNA methylation, development, and cancer. Genes Dev (2016) 30(7):733–50. doi: 10.1101/ gad.276868.115.

39. Koo GC, Tan SY, Tang T, Poon SL, Allen GE, Tan L, et al. Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma. Cancer Discov (2012) 2:911–20. doi: 10.1101/cancerdiscovery.20121441.

40. Koo GC, Tan SY, Tang T, Poon SL, Allen GE, Tan L, et al. Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma. Cancer Discov (2012) 2:911–20. doi: 10.1101/cancerdiscovery.20121441.

41. Calvete O, Martinez P, Garcia-Pavia P, Benitez-Buega C, Paumard-Hernandez R, Fernandez V, et al. A mutation in the POT1 gene is responsible for cardiac angiosarcoma in TP53-negative Li-Fraumeni-like families. Nat Commun (2015) 6:8383. doi: 10.1038/ncomms9383.

42. McMaster M, Sun C, Landi M, Savage S, Rotunno M, Yang X, et al. Germline mutations in protection of telomeres 1 in two families with Hodgkin lymphoma. Br J Haematol (2018) 181:372–7. doi: 10.1111/bjh.15203.

43. Srivastava A, Miao B, Skopelitou D, Kumar V, Kumar A, Paramasivam N, et al. A germline mutation in the POT1 gene is a candidate for familial non-medullary thyroid cancer. Cancers (Basel) (2020) 12:1441. doi: 10.3390/ cancers20121441.

44. Koo GC, Tan SY, Tang T, Poon SL, Allen GE, Tan L, et al. Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma. Cancer Discov (2012) 2:911–20. doi: 10.1101/cancerdiscovery.20121441.
mutations in the mantle cell subtype of lymphoma. Proc Natl Acad Sci USA (2003) 100(9):5372-7. doi: 10.1073/pnas.0831102100.

58. Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, et al. Mutational landscape of metastatic cancer derived from genomic profiling of extensive tissue sampling in 10,000 patients. Nat Med (2017) 23(7):703–13. doi: 10.1038/nm.4333.

59. Wong TN, Müller CA, Jotte MRM, Bagegni N, Baty JD, Schmidt AP, et al. Cellular stress response to contribute to the expansion of hematopoietic clones of varying leukemic potential. Nat Commun (2018) 9(1):455. doi: 10.1038/s41467-018-02858-0.

60. Margolese E, Jobanputra V, Jain P, Chen J, Ganapathi K, Nahum O, et al. Genetic landscape of T- and NK-cell post-transplant lymphoproliferative disorders. Oncotarget (2016) 7(25):37636–48. doi: 10.18632/oncotarget.9400.

61. Dobashi A, Tsyuma N, Asaka R, Togashi Y, Ueda K, Sakata S, et al. Frequent BCR alterations in extranodal NKT-cell lymphoma, nasal type. Genes Chromosomes Cancer (2016) 55(5):460–70. doi: 10.1002/gcc.23248.

62. McGranahan N and Swanton C. Clonal heterogeneity and tumor evolution: Past, present, and the future. Cell (2017) 168(4):613–28. doi: 10.1016/j.cell.2017.01.018.

63. Alexandrow LB, Nikol-Zainal S, Wedge DC, Aparicio SAJR, Bubajew S, Biaukin AV, et al. Signatures of mutational processes in human cancer. Nature (2013) 500(7465):415–21. doi: 10.1038/nature12477.

64. Kucab JE, Zou MA, Morgannella SM, Joel M, Nanda AS, Fukunaga M, et al. A compendium of mutational signatures of environmental agents. Cancer Cell (2017) 17(4):821–36.e16. doi: 10.1016/j.ccell.2019.03.001.

65. Jones CL, Degasperi A, Grandi V, Amarante TD, Amrumin P, Saroni P, et al. Spectrum of mutational signatures in T-cell lymphoma reveals a key role for UV radiation in cutaneous T-cell lymphoma. Sci Rep (2021) 11(1):17896. doi: 10.1038/s41598-021-83352-2.

66. Haradhati NJ, Polak P, Stojaron P, Covington KR, Shribrot E, Hiss JM, et al. Mutational strand asymmetries in cancer genomes reveal mechanisms of DNA damage repair. Cel (2016) 164(5):373–48. doi: 10.1016/j.cell.2015.12.050.

67. Prieto-Tores L, Rodrigo-Peña JM, Orlanda A, Bar M, Requena L, and Piris M. CD30-positive primary cutaneous lymphoproliferative disorders: Molecular alterations and targeted therapies. Haematologica (2019) 104(2):226–35. doi: 10.3324/haematol.2018.197192.

68. Velusamy T, Kiel MJ, Sahasrabuddhe AA, Rolland D, Dixon CA, Bailey NG, et al. A recurrent NPM1-TRY2 gene fusion in cutaneous CD30-positive lymphoproliferative disorders. Blood (2014) 124(25):3768–71. doi: 10.1182/blood-2014-07-788434.

69. Wada DA, Law ME, Ho ED, Cigado D, Ma L, Lim MS, et al. Specifity of IRF12 transfections for primary cutaneous anaplastic large cell lymphoma. A multicenter study of 204 skin biopsies. Mod Pathol (2011) 24(4):596–605. doi: 10.1038/modpathol.2010.225.

70. Gayden T, Sepulveda FE, Khoury-Quang DA, Pratt J, Valera ET, Garrigue J, et al. Frequent HRAS mutations in sporadic subcutaneous panniculitis-like T-cell lymphomas with hemophagocytic lymphohistiocytosis. J Invest Dermatol (2018) 140(2):1560–7. doi: 10.1016/j.jid.2017.09.002.

71. Polpraset C, Takeuchi Y, Kikuchi N, Yoshida K, Assanass T, Sithi W, et al. Frequent MYD88 mutations in sporadic subcutaneous panniculitis-like T-cell lymphoma. Blood Adv (2019) 3(4):588–95. doi: 10.1182/bloodadvances.2018028340.

72. Daniels J, Doukas PG, Escala MEM, Ringblom KG, Shih DJH, Yang J, et al. Cellular origins and genetic landscape of cutaneous gamma delta T-cell lymphomas. Nat Commun (2020) 11(1):4687–707. doi: 10.1038/s41467-020-15572-7.

73. Agar NS, Wedgeworth E, Crichton S, Mitchell TJ, Cox M, Ferreira S, et al. Survival outcomes and prognostic factors in mycosis Fungoides/Sézary syndrome: Validation of the revised international society for cutaneous Lymphomas/ European organisation for research and treatment of cancer staging proposal. J Clin Oncol (2010) 28(4):3780–9. doi: 10.1200/JCO.2009.27.7665.

74. Benton EC, Crichton S, Talpur R, Agar NS, Fields PA, Wedgeworth E, et al. A cutaneous lymphoma international prognostic index (CLIP-index) for mycosis fungoides and Sézary syndrome. Eur J Cancer (2013) 49(13):2689–93. doi: 10.1016/j.ejca.2013.04.018.

75. Chang LW, Patrone CC, Yang W, Rabionet R, Gallardo F, Espinet B, et al. CCR4 expression in cutaneous T cell lymphoma. J Am Acad Dermatol (2019) 80(6):1405–11. doi: 10.1016/j.jaad.2019.01.058.

76. Hain C, Stadler R and Kalinowski J. Unraveling the structural variations of T-cell lymphoma and its implications for personalized medicine. Eur J Cancer (2017) 74(6):415–23. doi: 10.1016/j.ejca.2017.01.058.

77. Prieto-Torres L, Rodriguez-Peña JM, Orlanda A, Ara M, Requena L, and Piris M. CD30-positive primary cutaneous lymphoproliferative disorders: Implications for immune suppression. Arch Dermatol (2010) 146(12):1382–8. doi: 10.1001/archdermatol.2010.200.

78. Boehns M, de Masson A, Andrillon A, Ram-Wolf C, Bizard L, Boisson M, et al. Mogamulizumab induces long term immune restoration and reshapes tumoral heterogeneity in Sézary syndrome. Eur J Cancer (2011) 47(6):1010–25. doi: 10.1111/j.1365-2123.2010.08714.x.

79. Leskahan AM, Ansell S, Armand P, Scott EC, Hawawi A, Gutzner M, et al. Dissemination in patients with relapsed or refractory hematologic malignancy: Preliminary results of a phase Ib study. J Clin Oncol (2016) 34(23):2698–704. doi: 10.1200/JCO.2015.65.9789.

80. Shen K, Liu Y, Cao X, Zhou D and Li J. Successful treatment of refractory Sézary syndrome by anti-PD-1 antibody (nivolumab). Ann Hematol (2017) 96(4):687–8. doi: 10.1007/s00277-017-2929-6.

81. Sivanan A, Surmanowicz P, Albusayan R, Hull P, Livrivon IV, Zhou Y, et al. Immunotherapy for cutaneous T-cell lymphoma: Current landscape and future developments. J Cutan Med Surg (2019) 23(5):537–44. doi: 10.1177/1203475419867610.

82. Park J, Daniels J, Wartewig T, Ringblom KG, Martinez-Escala ME, Choi S, et al. Integrated genomic analyses of cutaneous T-cell lymphoma reveal the molecular bases for disease heterogeneity. Blood (2021) 138(14):1225–36. doi: 10.1182/blood.2020096655.

83. Ratner L, Waldmann TA, Janakiram M and Brummer JE. Rapid progression of adult T-cell leukemia-lymphoma after PD-1 inhibitor therapy. N Engl J Med (2018) 378(20):1947–8. doi: 10.1056/NEJMoa1803181.

84. Querfeld C, Thompson JA, Taylor MH, DeSimone JA, Zain JM, Shustov AR, et al. Intratumoral T cell phenotype targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study. Lancet Haematol (2021) 8(11):e808–11. doi: 10.1016/S2352-3026(21)00071-4.

85. Johnson LDS, Banerjee S, Kruglov O, Villier NN, Horwitz SM, Leskahan A, et al. Targeting CD47 in Sézary syndrome with SRP790A. Blood Adv (2019). doi: 10.1182/bloodadvances.201803577.
98. Yakymiv Y, Marchisio S, Ortolan E, Bracci C, Senetta R, Rumore MR, et al. CD39/CD73 dysregulation and adenosine metabolism contribute to T cell immunosuppression in patients with Sézary syndrome. Blood (2022) 30: blood.2022017259. doi: 10.1182/blood.2022017259

99. Sonigo G, Alizée B, Dumont M, Thonnart N, Ram-Wolff C, de Masson A, et al. Involvement of the CD39/CD73/adenosine pathway in T-cell proliferation and NK cell-mediated antibody-dependent cell cytotoxicity in Sézary syndrome. Blood (2022) 139:2712–6. doi: 10.1182/blood.2021014782

100. Mei L, Zhang J, He K and Zhang J. Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: Where we stand. J Hematol Oncol (2019) 12(1):43. doi: 10.1186/s13045-019-0733-6

101. Gourley C, Balmain J, Ledermann JA, Serra V, Dent R, Loibl S, et al. Moving from poly (ADP-ribose) polymerase inhibition to targeting DNA repair and DNA damage response in cancer therapy. J Clin Oncol (2019) 37(25):2257–69. doi: 10.1200/JCO.18.02050

102. Scotto L, Serrano XJ, Zullo K, Kinahan C, Deng C, Sawas A, et al. ATM Inhibition overcomes resistance to histone deacetylase inhibitor due to p21 induction and cell cycle arrest. Oncotarget (2020) 11(37):3432–42. doi: 10.18632/oncotarget.27723

103. Ferrao PT, Bukczynska EP, Johnstone RW and McArthur GA. Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells. Oncogene (2012) 31(13):1661–72. doi: 10.1038/onc.2011.358

104. Ravi D, Beheshti A, Abermil N, Passero F, Sharma J, Coyle M, et al. Proteasomal inhibition by ixazomib induces CHK1 and MYC-dependent cell death in T-cell and Hodgkin lymphoma. Cancer Res (2016) 76(11):3319–31. doi: 10.1158/0008-5472.CAN-15-2477

105. Hughes CFM, Khot A, McCormack C, Lade S, Westerman DA, Twigger R, et al. Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: A comparative study of systemic therapy. Blood (2015) 125:71–81. doi: 10.1182/blood-2014-07-588236